Chronic kidney disease therapy options widen in non-diabetic populations
Finerenone in non-diabetic CKD, SGLT2 expansion past diabetes, and novel mechanism programs are restructuring CKD management beyond the diabetic kidney disease frame.
Chronic kidney disease has been a renin-angiotensin-blockade and SGLT2-in-diabetic-CKD category. Finerenone is now in late-stage trials in non-diabetic CKD, SGLT2 inhibitors are expanding into non-diabetic CKD with positive outcomes data, and novel mechanism programs (endothelin pathway, complement, other) are reading out. The category is widening past the diabetic-CKD frame that dominated the previous cycle.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.